

DAFTAR PUSTAKA

1. Shneker BF, Fountain NB. Epilepsy Bassel. *Disease-a-Month*. 2003;5029:426–78.
2. Sidhu R, Velayudam K, Barnes G. Pediatric Seizures. *Pediatr Rev*. 2013;34:313–42.
3. Laxer KD, Trinka E, Hirsch LJ, et al. The consequences of refractory epilepsy and its treatment. *Epilepsy Behav*. 2014;37:59-70.
4. Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. *Epilepsia*. 2013;54(3):551-563.
5. Keene DL. A Systematic Review of the Use of the Ketogenic Diet in Childhood Epilepsy. *Pediatr Neurol*. 2006;35(1):1-5.
6. Misiewicz Runyon A, So T-Y. The Use of Ketogenic Diet in Pediatric Patients with Epilepsy. *ISRN Pediatr*. 2012;2012:1-10.
7. Lefevre F, Aronson N. Ketogenic diet for the treatment of refractory epilepsy in children: A systematic review of efficacy. *Pediatrics*. 2000;105(4).
8. Schmidt M, Pfetzner N, Schwab M, Strauss I, Kämmerer U. Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: A pilot trial. *Nutr Metab*. 2011;8(1):54.
9. Martin-McGill KJ, Jackson CF, Bresnahan R, Levy RG, Cooper PN. Ketogenic diets for drug-resistant epilepsy. *Cochrane Database Syst Rev*. 2018;2018(11).
10. Zhu D, Wang M, Wang J, et al. Ketogenic diet effects on neurobehavioral development of children with intractable epilepsy: A prospective study. *Epilepsy Behav*. 2016;55(June 2013):87-91.
11. Caraballo RH, Fortini S, Fresler S, et al. Ketogenic diet in patients with Lennox-Gastaut syndrome. *Seizure*. 2014;23(9):751-755.
12. Williams TJ, Cervenka MC. The role for ketogenic diets in epilepsy and status epilepticus in adults. *Clin Neurophysiol Pract*. 2017;2:154-160.
13. Sampath a, Kossoff EH, Furth SL, Pyzik PL, Vining EP. Kidney stones and the ketogenic diet: risk factors and prevention. *J Child Neurol*. 2007;22(4):375-378.
14. Kwiterovich PO, Vining EPG, Pyzik P, Skolasky R, Freeman JM. Effect of a High-Fat Ketogenic Diet on Plasma Levels of Lipids, Lipoproteins, and Apolipoproteins in Children. *J Am Med Assoc*. 2003;290(7):912-920.
15. Dashti HM, Mathew TC, Hussein T, et al. Long-term effects of a ketogenic diet in obese

- patients. *Exp Clin Cardiol.* 2004;9(3):200-205.
16. Autry AR, Trevathan E, Van Naarden Braun K, Yeargin-Allsopp M. Increased risk of death among children with lennox-gastaut syndrome and infantile spasms. *J Child Neurol.* 2010;25(4):441-447.
17. Saleh TA, Stephen L. Lennox gastaut syndrome, review of the literature and a case report. *Head Face Med.* 2008;4(1):1-7.
18. Ec H, Jh C. Treatment of Lennox-Gastaut syndrome (Review). 2013;(2).
19. Arzimanoglou A, French J, Blume WT, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. *Lancet Neurol.* 2009;8(1):82-93.
20. Archer JS, Warren AEL, Jackson GD, Abbott DF. Conceptualizing Lennoxâ€“Gastaut Syndrome as a Secondary Network Epilepsy. *Front Neurol.* 2014;5(October):1-11.
21. Conradsen I, Wolf P, Sams T, Sorensen HBD, Beniczky S. Patterns of muscle activation during generalized tonic and tonic-clonic epileptic seizures. *Epilepsia.* 2011;52(11):2125-2132.
22. Viteva E. Basic cellular and molecular mechanisms of refractory epilepsy : a review of current hypotheses. *Mol Cell Epilepsy.* 2014;1(1):7-12.
23. Oguni H, Hayashi K, Osawa M. Long-term prognosis of Lennox-Gastaut syndrome. *Epilepsia.* 1996;37(SUPPL. 3):44-47.
24. Oguni H, Fukuyama Y, Tanaka T, et al. Myoclonic-astatic epilepsy of early childhood - Clinical and EEG analysis of myoclonic-astatic seizures, and discussions on the nosology of the syndrome. *Brain Dev.* 2001;23(7):757-764.
25. Rantala H, Putkonen T. Occurrence, outcome, and prognostic factors of infantile spasms and Lennox-Gastaut syndrome. *Epilepsia.* 1999;40(3):286-289.
26. Kothare S V., Trevathan E. Sudden death risk among children with epilepsy. *Neurology.* 2018;91(2):57-58.
27. Duchowny MS. Atonic seizures. *Pediatr Rev.* 1987;9(2):43-49. <http://pedsinreview.aappublications.org/content/pedsinreview/9/2/43.full.pdf>.
28. Kovac S, Diehl B. Atonic phenomena in focal seizures : Nomenclature , clinical findings and pathophysiological concepts. *Seizure Eur J Epilepsy.* 2012;21(8):561-567.
29. Fisher RS, Cross H, French JA, Higurashi N, Hirsch E, Jansen, Floor E. et al. Operational Classification of Seizure Types by the International League Against Epilepsy. *J Child Neurol.* 2012;53:45–52. 30.

30. Saygi S, Erol I, Alehan F. Early clinical predictors of intractable epilepsy in childhood. *Turkish J Med Sci*. 2014;44(3):490-495. doi:10.3906/sag-1302-4.
31. Go C, Snead OC. Pharmacologically intractable epilepsy in children: Diagnosis and preoperative evaluation. *Neurosurg Focus*. 2008;25(3):1-7.
32. Kovac S, Nachev P, Rodionov R, et al. Neck atonia with a focal stimulation-induced seizure arising from the SMA: Pathophysiological considerations. *Epilepsy Behav*. 2012;24(4):503-506.
33. Ikeda A. Role of primary sensorimotor cortices in generating inhibitory motor response in humans. *Brain*. 2000;123(8):1710-1721.
34. Ikeda A, Ohara S, Matsumoto R, et al. Role of primary sensorimotor cortices in generating inhibitory motor response in humans. *Brain*. 2000;123(8):1710-1721.
35. Sankaraneni R, Lachhwani D. Antiepileptic drugs-a review. *Pediatr Ann*. 2015;44(2):e36-e42.
36. Vining EPG. Tonic and atonic seizures: Medical therapy and ketogenic diet. *Epilepsia*. 2009;50(SUPPL. 8):21-24.
37. De Lima PA, De Brito Sampaio LP, Teixeira Damasceno NR. Neurobiochemical mechanisms of a ketogenic diet in refractory epilepsy. *Clinics*. 2014;69(10):699-705.
38. Masino SA, Rho JM. *Mechanisms of Ketogenic Diet Action*. Vol 51.; 2010.
39. Verhelst H, Boon P, Buyse G, et al. Steroids in intractable childhood epilepsy: Clinical experience and review of the literature. *Seizure*. 2005;14(6):412-421.
40. Almaabdi KH, Alshehri RO, Althubiti AA, et al. Intravenous methylprednisolone for intractable childhood epilepsy. *Pediatr Neurol*. 2014;50(4):334-336.
41. Kim EH, Ko TS. Cognitive impairment in childhood onset epilepsy: Up-to-date information about its causes. *Korean J Pediatr*. 2016;59(4):155-164.
42. Wu Q, Wang H, Fan YY, et al. Ketogenic diet effects on 52 children with pharmacoresistant epileptic encephalopathy: A clinical prospective study. *Brain Behav*. 2018;8(5):1-8.
43. Fosi T, Lax-Pericall MT, Scott RC, Neville BG, Aylett SE. Methylphenidate treatment of attention deficit hyperactivity disorder in young people with learning disability and difficult-to-treat epilepsy: Evidence of clinical benefit. *Epilepsia*. 2013;54(12):2071-2081.
44. Groesbeck DK, Bluml RM, Kossoff EH. Long-term use of the ketogenic diet in the treatment of epilepsy. *Dev Med Child Neurol*. 2006;48(12):978-981.

45. Freeman JM, Kossoff EH, Hartman AL. The ketogenic diet: One decade later. *Pediatrics*. 2007;119(3):535-543.
46. Coppola G, Natale F, Torino A, et al. The impact of the ketogenic diet on arterial morphology and endothelial function in children and young adults with epilepsy: A case-control study. *Seizure*. 2014;23(4):260-265.
47. Vijayasarathi A, Goldberg SJ. Comparison of Carotid Intima-Media Thickness in Pediatric Patients with Metabolic Syndrome, Heterozygous Familial Hyperlipidemia and Normals. *J Lipids*. 2014;2014:1-7.
48. Cotter DG, Ercal B, Huang X, et al. Ketogenesis prevents diet-induced fatty liver injury and hyperglycemia. *J Clin Invest*. 2014;124(12):5175-5190.
49. Partsalaki I, Karvela A, Spiliotis BE. Metabolic impact of a ketogenic diet compared to a hypocaloric diet in obese children and adolescents. *J Pediatr Endocrinol Metab*. 2012;25(7-8):697-704.
50. Baroncini LAV, Sylvestre L de C, Pecoits Filho R. Assessment of intima-media thickness in healthy children aged 1 to 15 years. *Arq Bras Cardiol*. 2016;106(4):327-332.